

## **Guillaume Laverdure Appointed CEO of Medicom Group**



Canada-based Medicom Group, a world leader in the production and distribution of infection prevention and control solutions , is pleased to announce the appointment of Guillaume Laverdure as CEO. He succeeds Ronald Reuben, founder of the company, and becomes the second person in the history of the group to hold this position. Mr. Laverdure has most recently held the position of Chief Operating Officer within the Group.

A native of France, Mr. Laverdure is a graduate of HEC Paris and Harvard Business School. He joined Medicom in 2009 following an international career in Europe and the United States in finance, operations and general management. He led the company's transformation to masks and N95 respirators and oversaw the opening of six new personal protective equipment production facilities on three continents during the COVID-19 pandemic.

"Guillaume embodies the competency and humanity one would expect in a leader. I have had the pleasure of seeing him in action, defining his vision, accomplishing major strategic projects and interacting with our team members with respect and empathy. Medicom is at a pivotal point in its journey and I am confident that Guillaume will take the company to the next level. I will continue to lend my support where needed, as I assume the role of executive chairman effective today," commented Ronald Reuben, founder and new executive chairman of Medicom.

"It is with great humility and a great sense of privilege that I take the reins of the Medicom Group after having held several positions for over 13 years. I thank my friend Ronald for his trust and for all the years of good advice and leadership. Medicom has become a symbol of excellence in our industry thanks to the unwavering commitment of each member of our team to provide the best possible products to our customers. It is with this same mission to live up to our pride in protection that I begin my new mandate," said Guillaume Laverdure, Medicom's new CEO.

Source: Medicom Group

Published on : Sun, 14 Aug 2022